- Previous close
0.0170 - Open
0.0170 - Bid 0.0180 x 62500000
- Ask 0.0180 x 81500000
- Day's range
0.0170 - 0.0170 - 52-week range
0.0110 - 0.0220 - Volume
25,970 - Avg. Volume
418,839 - Market cap (intra-day)
21.748M - Beta (5Y monthly) 0.42
- PE ratio (TTM)
∞ - EPS (TTM)
0.0000 - Earnings date 14 Nov 2024 - 18 Nov 2024
- Forward dividend & yield --
- Ex-dividend date --
- 1y target est
--
BLIS Technologies Limited, together with its subsidiaries, develops and sells healthcare products based on strains of bacteria that produce bacteriocin activity. The company offers BLIS K12, an oral probiotic supplement to support ear, nose, and throat health, as well as for enhancing immunity and bad breath; BLIS M18, an oral probiotic to support teeth and gums health; and BLIS Q24, a probiotic supplement to balance the skin microbiome, restoring the health, clarity, and radiance. It has operations in New Zealand, Asia Pacific, Europe, the Middle East, Africa, and North America. The company was incorporated in 2000 and is based in Dunedin, New Zealand.
www.blis.co.nz39
Full-time employees
31 March
Fiscal year ends
Healthcare
Sector
Biotechnology
Industry
Recent news: BLT.NZ
View more
Performance overview: BLT.NZ
Trailing total returns as of 8/11/2024, which may include dividends or other distributions. Benchmark is
.YTD return
1-year return
3-year return
5-year return
Compare to: BLT.NZ
Select to analyse similar companies using key performance metrics; select up to four stocks.
Statistics: BLT.NZ
View moreValuation measures
Market cap
21.75M
Enterprise value
13.54M
Trailing P/E
34.00
Forward P/E
--
PEG ratio (5-yr expected)
--
Price/sales (ttm)
2.07
Price/book (mrq)
1.89
Enterprise value/revenue
1.29
Enterprise value/EBITDA
10.79
Financial highlights
Profitability and income statement
Profit margin
5.58%
Return on assets (ttm)
1.56%
Return on equity (ttm)
5.79%
Revenue (ttm)
11.57M
Net income avi to common (ttm)
646k
Diluted EPS (ttm)
0.0000
Balance sheet and cash flow
Total cash (mrq)
8.52M
Total debt/equity (mrq)
3.39%
Levered free cash flow (ttm)
11.88k